Curriculum vitae of CUG binding protein 1 (CELF1) in homeostasis and diseases: a systematic review
RNA-binding proteins (RBPs) are kinds of proteins with either singular or multiple RNA-binding domains (RBDs), and they can assembly into ribonucleic acid–protein complexes, which mediate transportation, editing, splicing, stabilization, translational efficiency, or epigenetic modifications of their binding RNA partners, and thereby modulate various physiological and pathological processes. CUG-BP, Elav-like family 1 (CELF1) is a member of the CELF family of RBPs with high affinity to the GU-rich elements in mRNA, and thus exerting control over critical processes including mRNA splicing, translation, and decay. Mounting studies support that CELF1 is correlated with occurrence, genesis and development and represents a potential therapeutical target for these malignant diseases. Herein, we present the structure and function of CELF1, outline its role and regulatory mechanisms in varieties of homeostasis and diseases, summarize the identified CELF1 regulators and their structure–activity relationships, and prospect the current challenges and their solutions during studies on CELF1 functions and corresponding drug discovery, which will facilitate the establishment of a targeted regulatory network for CELF1 in diseases and advance CELF1 as a potential drug target for disease therapy. Graphical Abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Cellular & molecular biology letters - 29(2024), 1 vom: 05. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qin, Wan‑Jia [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s11658-024-00556-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055030564 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055030564 | ||
| 003 | DE-627 | ||
| 005 | 20240306064705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s11658-024-00556-y |2 doi | |
| 035 | |a (DE-627)SPR055030564 | ||
| 035 | |a (SPR)s11658-024-00556-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qin, Wan‑Jia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Curriculum vitae of CUG binding protein 1 (CELF1) in homeostasis and diseases: a systematic review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a RNA-binding proteins (RBPs) are kinds of proteins with either singular or multiple RNA-binding domains (RBDs), and they can assembly into ribonucleic acid–protein complexes, which mediate transportation, editing, splicing, stabilization, translational efficiency, or epigenetic modifications of their binding RNA partners, and thereby modulate various physiological and pathological processes. CUG-BP, Elav-like family 1 (CELF1) is a member of the CELF family of RBPs with high affinity to the GU-rich elements in mRNA, and thus exerting control over critical processes including mRNA splicing, translation, and decay. Mounting studies support that CELF1 is correlated with occurrence, genesis and development and represents a potential therapeutical target for these malignant diseases. Herein, we present the structure and function of CELF1, outline its role and regulatory mechanisms in varieties of homeostasis and diseases, summarize the identified CELF1 regulators and their structure–activity relationships, and prospect the current challenges and their solutions during studies on CELF1 functions and corresponding drug discovery, which will facilitate the establishment of a targeted regulatory network for CELF1 in diseases and advance CELF1 as a potential drug target for disease therapy. Graphical Abstract | ||
| 650 | 4 | |a CELF1 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a RNA-binding protein |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Diseases |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cancer therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inhibitor |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Shi, Jin-Jin |4 aut | |
| 700 | 1 | |a Chen, Ru-Yi |4 aut | |
| 700 | 1 | |a Li, Chang-Yun |4 aut | |
| 700 | 1 | |a Liu, Yan-Jun |4 aut | |
| 700 | 1 | |a Lu, Jian-Fei |4 aut | |
| 700 | 1 | |a Yang, Guan-Jun |0 (orcid)0000-0003-1291-8727 |4 aut | |
| 700 | 1 | |a Cao, Jia-Feng |4 aut | |
| 700 | 1 | |a Chen, Jiong |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cellular & molecular biology letters |d London : BioMed Central, 1996 |g 29(2024), 1 vom: 05. März |w (DE-627)SPR021339902 |w (DE-600)2108724-6 |x 1689-1392 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:1 |g day:05 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s11658-024-00556-y |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 1 |b 05 |c 03 | ||